Congressional committee investigates former NCI Director Richard Klausner’s role in $40 million Harvard contract; NIH begins internal review. Klausner: investigation casts “strange innuendoes.” Text of committee’s letter.
Also in this 12-page issue: NCI gives Doroshow and Fine “lead role” in clinical trials system review.
NCI program announcement available, contract awards listed.
Trending Stories
- Brawley: ACS prostate cancer screening guideline should say no to “mass screening”
- NCI’s Letai, FDA’s Diamantas identify strategies to speed up cancer trials
Letai: 150 days to start a cancer trial is too long—cancer centers need to accept a little risk - ACS strengthens recommendation for prostate cancer screening
Many will hear the endorsement and ignore the limitations - Kay “Taddy” Dickersin, NBCC co-founder, dies at 74
- CMS rule cuts overall oncology payments by estimated 2%
Final rule slashes 340B, moves toward site-neutrality - Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives









